Professor Dame Louise Johnson

Professor Dame Louise Johnson is an expert in the field of structural biology. She was appointed as David Phillips Professor of Molecular Biophysics and Professorial Fellow at Corpus Christi, Oxford in 1990 . The focus of her current research is on cell cycle regulatory proteins and protein kinases. She was elected as Fellow of the Royal Society in 1990. In 2003 she took up the position of Director of Life Sciences at the Diamond Light Source, the UK's new synchrotron source that will provide new opportunities for both the Life and Physical Sciences.

Professor David Kerr

Professor David Kerr is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, University of Oxford where he is currently involved in building a new Institute for Cancer Medicine. He has an international reputation for research in to and the treatment of colorectal cancer, and is developing new approaches to cancer treatment involving gene therapy. His work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation. He was elected Fellow of the Academy of Medical Sciences in 2000 and appointed Commander of the British Empire in 2002.

Professor Sir Ravinder Nath "Tiny" Maini

Professor Sir Ravinder Nath "Tiny" Maini, is recently retired as the Director of the Kennedy Research Institute at Imperial College, London where he led a team of researchers over a 15 year period looking for new treatments for rheumatoid arthritis. In 2003 he was a co-recipient of the prestigious 2003 Albert Lasker Award for Clinical Medical Research for the discovery of anti-TNF (tumour necrosis factor) as an effective treatment for rheumatoid arthritis and other related diseases. For this work he received a knighthood in 2003.

Professor Peter Ratcliffe

Professor Peter Ratcliffe is Nuffield Professor of Medicine and Head of Department at the University of Oxford. He trained as a Nephrologist and was Academic Director of Renal Medicine prior to appointment to the current position in 2004. He has a broad range of interests in clinical and experimental medicine and has worked extensively of hypoxia signalling pathways, publishing over 150 peer-reviewed manuscripts in the this and related fields. In 2002 he was elected Fellow of the Royal Society, and in 2006 member of EMBO.

Dr Michael Sundstrom

Dr Michael Sundstrom leads the Structural Genomics Consortium operations at the site in Oxford, UK. His previous experience includes PhD studies and Post-Doctoral training in protein crystallography and protein biochemistry in Sweden plus solid experience from structural biology/structure-based drug design approaches in the Pharmaceutical industry with companies such as Pharmacia.